Summary
Our previous studies showed that intracerebral infusion of argatroban, a specific thrombin inhibitor, reduces brain edema and neurological deficits in a C6 glioma model. The present study investigated whether systemic argatroban administration can reduce glioma mass and neurological deficits and extend survival time in C6 and F98 gliomas. Rat C6 or F98 glioma cells were infused into the right caudate of adult male Fischer 344 rats. Osmotic minipump loaded with argatroban (0.3 mg/hour) or vehicle was implanted into abdomen immediately after glioma implantation. Tumor mass was determined at day 9. Over the period of the experiment, the animals underwent behavioral testing (forelimb placing and forelimb use asymmetry). In addition, survival time was tested in the F98 glioma model. In C6 glioma, argatroban reduced glioma mass (p < 0.05) and neurological deficits (p < 0.05) at day 9. In F98 glioma, agratroban prolonged the survival time (p < 0.05) and reduced the body weight loss (84 ± 15 gram vs. 99 ± 2 gram in the vehicle group, P < 0.05). In conclusion, systemic use of argatroban reduced tumor mass and neurological deficits, and prolonged survival time. These results suggest that thrombin plays a key role in glioma growth and thrombin inhibition with argatroban may be a novel treatment for gliomas.
This study was supported by Mitsubishi Pharma Corporation.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Cavanaugh KP, Gurwitz D, Cunningham DD, Bradshaw RA (1990) Reciprocal modulation of astrocyte stellation by thrombin and protease nexin-1. J Neurochem 54: 1735–1743
Coughlin SR (2000) Thrombin signalling and protease-activated receptors. Nature 407: 258–264
Hua Y, Keep RF, Schallert T, Hoff JT, Xi G (2003) A thrombin inhibitor reduces brain edema, glioma mass and neurological deficits in a rat glioma model. Acta Neurochir (Wien) [Suppl] 86: 503–506
Hua Y, Schallert T, Keep RF, Wu J, Hoff JT, Xi G (2002) Behavioral tests after intracerebral hemorrhage in the rat. Stroke 33: 2478–2484
Hursting MJ, Alford KL, Becker JC, Brooks RL, Joffrion JL, Knappenberger GD, Kogan PW, Kogan TP, McKinney AA, Schwarz RP, Jr (1997) Novastan (brand of argatroban): a small-molecule, direct thrombin inhibitor. Sem Thrombos Hemostas 23: 503–516
Kitaoka T, Hua Y, Xi G, Hoff JT, Keep RF (2002) Delayed argatroban treatment reduces edema in a rat model of intracerebral hemorrhage. Stroke 33: 3012–3018
Maragoudakis ME, Tsopanoglou NE (2000) On the mechanism(s) of thrombin induced angiogenesis. Adv Exp Med Biol 476: 47–55
McKeage K, Plosker GL (2001) Argatroban. Drugs 61: 515–522
Medrano EE, Cafferata EG, Larcher F (1987) Role of thrombin in the proliferative response of T-47D mammary tumor cells. Mitogenic action and pleiotropic modifications induced together with epidermal growth factor and insulin. Exp Cell Res 172:354–364
Neveu I, Jehan F, Jandrot-Perrus M, Wion D, Brachet P (1993) Enhancement of the synthesis and secretion of nerve growth factor in primary cultures of glial cells by proteases: a possible involvement of thrombin. J Neurochem 60: 858–867
O’Reilly MS, Pirie-Shepherd S, Lane WS, Folkman J (1999) Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science 285: 1926–1928
Ogiichi T, Hirashima Y, Nakamura S, Endo S, Kurimoto M, Takaku A (2000) Tissue factor and cancer procoagulant expressed by glioma cells participate in their thrombin-mediated proliferation. J Neuro Oncol 46: 1–9
Ornstein DL, Meehan KR, Zacharski LR (2002) The coagulation system as a target for the treatment of human gliomas. Sem Thromb Hemostas 28: 19–28
Rickles FR, Patierno S, Fernandez PM (2003) Tissue factor, thrombin, and cancer. Chest 124: 58S–68S
Schallert T, Leasure JL, Kolb B (2000a) Experience-associated structural events, subependymal cellular proliferative activity, and functional recovery after injury to the central nervous system. J Cereb Blood Flow Metab 20: 1513–1528
Schallert T, Fleming SM, Leasure JL, Tillerson JL, Bland ST (2000b) CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology 39:777–787
Trojan J, Johnson TR, Rudin SD, Ilan J, Tykocinski ML (1993) Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor I RNA. Science 259: 94–97
Yamahata H, Takeshima H, Kuratsu J, Sarker KP, Tanioka K, Wakimaru N, Nakata M, Kitajima I, Maruyama I (2002) The role of thrombin in the neo-vascularization of malignant gliomas: an intrinsic modulator for the up-regulation of vascular endothelial growth factor. Int J Oncol 20: 921–928
Zacharski LR, Ornstein DL (1998) Heparin and cancer. Thromb Haemostas 80: 10–23
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Springer-Verlag
About this paper
Cite this paper
Hua, Y. et al. (2005). Systemic use of argatroban reduces tumor mass, attenuates neurological deficits and prolongs survival time in rat glioma models. In: Poon, W.S., et al. Intracranial Pressure and Brain Monitoring XII. Acta Neurochirurgica Supplementum, vol 95. Springer, Vienna. https://doi.org/10.1007/3-211-32318-X_82
Download citation
DOI: https://doi.org/10.1007/3-211-32318-X_82
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-24336-7
Online ISBN: 978-3-211-32318-2
eBook Packages: MedicineMedicine (R0)